Study type: Human research · Status: Evidence verified by machine against declared source

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.

Critical care (London, England) · 2013

Study scale: A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group.

Product or molecular entity relationships

Thymosin Alpha 1: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Adjunctive treatment may be efficient and require further investigation.

Study design

Eligible patients admitted in ICU with severe sepsis were randomly allocated by a central randomization center to the control group or Tα1 group (1:1 ratio).

Participants or experimental system

The trial is to evaluate whether Tα1 improves 28-day all-cause mortality rates and immunofunction in patients with severe sepsis.

Study scale

A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group.

Intervention or exposure

Notably, recent development in immunomodulatory research has indicated the beneficial effect of Tα1 treatment in septic patients.

Comparator

The mortalities from any cause within 28 days in the Tα1 group and control group were 26.0% and 35.0% respectively with a marginal P value (nonstratified analysis, P = 0.062; log rank, P = 0.049); the relative risk of death in the Tα1 group as compared to the control group was 0.74 (95% CI 0.54 to 1.02).

Outcomes examined

The primary outcome was death from any cause and was assessed 28 days after enrollment.

Key findings

Severe sepsis is associated with a high mortality rate despite implementation of guideline recommendations.

Limitations and uncertainty

Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.